HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposes $19 Mil. In Cosmetics User Fees To Support Enhanced Oversight

This article was originally published in The Rose Sheet

Executive Summary

With almost $19 million in user fees proposed for cosmetics manufacturers in FDA’s budget request, the agency intends to overhaul regulation of the personal-care industry.

You may also be interested in...



FDA Seeks $19 Mil. From Cosmetics Firms In User-Fee-Heavy 2014 Budget

Collecting user fees from cosmetics manufacturers to the tune of $19 million would help “improve FDA’s capacity to promote greater safety and understanding of cosmetic products,” the agency says. FDA submitted a similar proposal last year and will be up against challenges again in securing the necessary legislation.

Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012

“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.

Stakeholders Hopeful New Congress Addresses Cosmetics Legislation

Following the Nov 6. elections, cosmetics industry stakeholders look to the future. The Campaign for Safe Cosmetics is “excited” about prospects in the new Congress, while the Personal Care Products Council says it’s too early to predict what lies ahead because committee assignments have not yet been announced.

Related Content

Topics

UsernamePublicRestriction

Register

RS017967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel